New hemophilia drugs aim to simplify treatment - (Yahoo!Finance via NewsPoints Desk)

  • Several drugmakers are developing treatments for haemophilia that could dramatically reduce the number of injections needed to prevent bleeding events, as reported Yahoo!Finance Friday.
  • The FDA is expected to issue a decision on Biogen Idec and Swedish Orphan Biovitrum's haemophilia B clotting factor Alprolix by mid-2014, while Novo Nordisk plans to submit its long-acting haemophilia B treatment N9-GP for regulatory approval next year.
  • Morningstar analysts said that the market for haemophilia drugs, including Baxter's Advate and Pfizer's Xyntha, could grow to $11.4 billion by 2016.
  • Additionally, an FDA decision on Biogen Idec's hemophilia A therapy Eloctate is anticipated later this year, while a regulatory submission of Baxter's long-lasting hemophilia A medicine may occur by the end of the year.
  • Meanwhile, Bayer and CSL Behring have long-lasting haemophilia therapies in late-stage development, while Pfizer's long-lasting products are in the "discovery" stage.
  • Separately, drugmakers including Sangamo BioSciences and BioMarin Pharmaceutical are attempting to develop methods to replace defective haemophilia genes, which would permit patients to produce their own clotting factors.

To read more NewsPoints articles, click here.

Reference Articles